AIM:MTPH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Midatech Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MTPH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.5%

MTPH

-1.7%

GB Biotechs

-5.1%

GB Market


1 Year Return

-66.7%

MTPH

41.2%

GB Biotechs

-20.0%

GB Market

Return vs Industry: MTPH underperformed the UK Biotechs industry which returned 45.1% over the past year.

Return vs Market: MTPH underperformed the UK Market which returned -19.3% over the past year.


Shareholder returns

MTPHIndustryMarket
7 Day-8.5%-1.7%-5.1%
30 Day-8.5%7.1%-4.3%
90 Day-19.4%7.1%-4.5%
1 Year-66.7%-66.7%42.3%41.2%-17.0%-20.0%
3 Year-97.3%-97.3%5.7%4.1%-13.6%-24.3%
5 Year-99.5%-99.5%36.0%33.1%10.2%-14.6%

Price Volatility Vs. Market

How volatile is Midatech Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Midatech Pharma undervalued compared to its fair value and its price relative to the market?

2.33x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MTPH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MTPH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MTPH is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: MTPH is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MTPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MTPH is good value based on its PB Ratio (2.3x) compared to the GB Biotechs industry average (6.2x).


Next Steps

Future Growth

How is Midatech Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Midatech Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Midatech Pharma performed over the past 5 years?

-3.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MTPH is currently unprofitable.

Growing Profit Margin: MTPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MTPH is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.

Accelerating Growth: Unable to compare MTPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MTPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).


Return on Equity

High ROE: MTPH has a negative Return on Equity (-486.89%), as it is currently unprofitable.


Next Steps

Financial Health

How is Midatech Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: MTPH's short term assets (£10.3M) exceed its short term liabilities (£7.3M).

Long Term Liabilities: MTPH's short term assets (£10.3M) exceed its long term liabilities (£107.0K).


Debt to Equity History and Analysis

Debt Level: MTPH's debt to equity ratio (70.2%) is considered high.

Reducing Debt: MTPH's debt to equity ratio has increased from 4.2% to 70.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MTPH has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: MTPH is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Midatech Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MTPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MTPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MTPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MTPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MTPH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Stephen Stamp (58 yo)

0.58

Tenure

UK£206,852

Compensation

Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Midatech Pharma plc since September 9, 2019. He serves as Chief Executive Officer at Midatech Pharma plc since March 31, 2020. He serv ...


CEO Compensation Analysis

Compensation vs Market: Stephen's total compensation ($USD267.99K) is about average for companies of similar size in the UK market ($USD349.56K).

Compensation vs Earnings: Insufficient data to compare Stephen's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Stephen Stamp
CEO, CFO & Director0.58yrUK£206.85k0.079%
£ 13.5k
Tim Sparey
Chief Business Officerno datano datano data
Justin Barry
Head of Manufacturingno datano datano data
Steve Damment
Executive Vice President of Research & Development2.58yrsno data0.0032%
£ 539.8
David Benharris
President of Midatech Pharma US Inc4.75yrsno datano data

2.6yrs

Average Tenure

58yo

Average Age

Experienced Management: MTPH's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stephen Stamp
CEO, CFO & Director0.58yrUK£206.85k0.079%
£ 13.5k
Simon Turton
Senior Independent Non-Executive Director5.83yrsUK£30.40k0.081%
£ 13.9k
Rolf Stahel
Independent Non-Executive Chairman6.58yrsUK£90.00k0.039%
£ 6.6k
Daniel McCurdy
Member of Scientific Advisory Boardno datano datano data
Sijmen de Vries
Independent Non-Executive Director16yrsUK£30.40k0.035%
£ 5.9k
Michael Natan
Member of Scientific Advisory Boardno datano datano data
Francesco Stellaci
Chairman of Scientific Advisory Boardno datano datano data
David Male
Member of Scientific Advisory Boardno datano datano data
Lorraine O'Driscoll
Member of Scientific Advisory Boardno datano datano data
Soledad Penades
Member of Scientific Advisory Boardno datano datano data
Jean-Christophe Roux
Member of Scientific Advisory Boardno datano datano data
Silke Krol
Member of Scientific Advisory Boardno datano datano data

6.2yrs

Average Tenure

61yo

Average Age

Experienced Board: MTPH's board of directors are considered experienced (6.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 168.5%.


Top Shareholders

Company Information

Midatech Pharma plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Midatech Pharma plc
  • Ticker: MTPH
  • Exchange: AIM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£17.030m
  • Shares outstanding: 63.07m
  • Website: https://www.midatechpharma.com

Number of Employees


Location

  • Midatech Pharma plc
  • Oddfellows House
  • 19 Newport Road
  • Cardiff
  • South Glamorgan
  • CF24 0AA
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MTPHAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2014
5MPADB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2014
MTPNasdaqCM (Nasdaq Capital Market)SPON ADS EACH REP 5 ORD SHS(R/S)USUSDDec 2015
5MPABST (Boerse-Stuttgart)SPON ADS EACH REP 5 ORD SHS(R/S)DEEURDec 2015
5MPDDB (Deutsche Boerse AG)SPON ADS EACH REP 5 ORD SHS(R/S)DEEURDec 2015

Biography

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/30 20:48
End of Day Share Price2020/10/30 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.